TickerFacts.

Apimeds Pharmaceuticals US, Inc. (APUS): Shareholders' Equity

Annual figures by period end, from SEC filings.

$153.35M
As of 2025-12-31
$106.45M
As of 2026-06-30
2023-12-31: $31.9K2024-12-31: -$1.36M2025-12-31: $153.35M$153.35M
2023-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$153.35Mn/m2026-05-04, Balance as of period end
2024-12-31-$1.36Mn/m2026-05-04, Balance as of period end
2023-12-31$31.9Kn/a2025-04-15, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Apimeds Pharmaceuticals US, Inc. (APUS)2025-12-31$153.35Mn/m
Cypherpunk Technologies Inc. (CYPH)2025-12-31$153.51M+338.0%
Transcode Therapeutics, Inc. (RNAZ)2025-12-31$10.34Mn/m
Gyre Therapeutics, Inc. (GYRE)2025-12-31$106.03M+67.5%
Climb Bio, Inc. (CLYM)2025-12-31$160.47M-24.3%
Aclaris Therapeutics, Inc. (ACRS)2025-12-31$103.08M-33.7%
Aquestive Therapeutics, Inc. (AQST)2025-12-31-$33.66Mn/m
Corbus Pharmaceuticals Holdings, Inc. (CRBP)2025-12-31$147.50M+3.6%
Eledon Pharmaceuticals, Inc. (ELDN)2025-12-31$81.08M+29.8%

Compare APUS, CYPH, RNAZ, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗